Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.

Frontiers in immunology(2022)

引用 2|浏览17
暂无评分
摘要
Previous studies proposed no predictive difference between original TMB and modified TMB, and original TMB contains some genes with no predictive value. To demonstrate that fewer genetic tests are sufficient to predict immunotherapy efficacy, we used machine learning to screen out gene panels, which are used to calculate TMB. Therefore, we obtained the 88-gene panel, which showed the favorable prediction performance and stratification effect compared to the original TMB.
更多
查看译文
关键词
gene,immunotherapy,machine learning (ML),non-small cell lung cancer (NSCLC),tumor mutational burden (TMB)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要